Skip to main content
OpenTrials

Clinical trial condition

Lymphoproliferative Disorders

Explore clinical trials studying Lymphoproliferative Disorders. Study availability and eligibility vary by location and protocol.

10,057 public trials 2,038 recruiting studies
Refine in advanced search Browse all conditions

Lymphoproliferative Disorders trial results

Completed

Combination Chemotherapy in Treating Young Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia

NCT00967057

Conditions
Hematologic Diseases, Hemic and Lymphatic Diseases, Immune System Diseases, +8 more
Locations
  • Women's and Children's Hospital North Adelaide, South Australia, Australia
  • Birmingham Children's Hospital Birmingham, England, United Kingdom
  • Bristol Royal Hospital for Children Bristol, England, United Kingdom
  • Great Ormond Street Hospital for Children London, England, United Kingdom
View Trial Details
Completed

Chemotherapy and Peripheral Stem Cell Transplant With or Without Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma

NCT00012051

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
Locations
  • U.Z. Gasthuisberg Leuven, Belgium
  • Jeroen Bosch Ziekenhuis 's-Hertogenbosch, Netherlands
  • Meander Medisch Centrum Amersfoort, Netherlands
  • Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital Amsterdam, Netherlands
View all 17 locations
View Trial Details
Completed

Study of Mapatumumab in Combination With Bortezomib (Velcade) and Bortezomib Alone in Subjects With Relapsed or Refractory Multiple Myeloma

NCT00315757

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Mayo Clinic Arizona Scottsdale, Arizona, United States
  • Scripps Clinic Medical Group, Inc. La Jolla, California, United States
  • Cancer and Blood Disorders Center Lecanto, Florida, United States
  • University of Chicago Chicago, Illinois, United States
View all 20 locations
View Trial Details
Completed

Fludarabine Combined With Either Alemtuzumab or Rituximab in Treating Patients With Refractory or Relapsed B-Cell Chronic Lymphocytic Leukemia

NCT00086775

Conditions
Chronic Disease, Disease Attributes, Hematologic Diseases, +13 more
Locations
  • Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute Boston, Massachusetts, United States
  • Jackson Oncology Associates, PLLC Jackson, Mississippi, United States
  • Cancer Institute of New Jersey at Robert Wood Johnson University Hospital New Brunswick, New Jersey, United States
  • Western Pennsylvania Cancer Institute Pittsburgh, Pennsylvania, United States
View Trial Details

Related conditions